These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 12001122

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J.
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus.
    Bonatz G, Frahm SO, Klapper W, Helfenstein A, Heidorn K, Jonat W, Krupp G, Parwaresch R, Rudolph P.
    Hum Pathol; 2001 Jun; 32(6):605-14. PubMed ID: 11431715
    [Abstract] [Full Text] [Related]

  • 5. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J, Zhang DB, Luo SK, Zhao Y, Huang BH, Gu JL.
    Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
    [Abstract] [Full Text] [Related]

  • 6. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F, Minoia C, Favoino E, Prete M, Dammacco F.
    Blood Cells Mol Dis; 2009 Sep; 42(1):71-6. PubMed ID: 18996035
    [Abstract] [Full Text] [Related]

  • 7. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM.
    Cancer; 2003 May 15; 97(10):2440-52. PubMed ID: 12733143
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V, Zemanova M, Minarik J, Bacovsky J, Ordeltova M, Indrak K, Budikova M, Dusek L, Farbiakova V.
    Neoplasma; 2006 May 15; 53(4):277-84. PubMed ID: 16830053
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.
    Cancer; 2007 Aug 15; 110(4):824-9. PubMed ID: 17594696
    [Abstract] [Full Text] [Related]

  • 14. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
    Scudla V, Pika T, Budíková M, Ordeltová M, Minarík J, Zemanová M, Bacovský J, Srovnalík K, Ceská myelomová skupina.
    Cas Lek Cesk; 2006 Aug 15; 145(12):929-35. PubMed ID: 17323615
    [Abstract] [Full Text] [Related]

  • 15. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A, Zepeda G, Guzmán R, Talavera A, García EL, Díaz-Maqueo JC.
    Rev Invest Clin; 1992 Aug 15; 44(2):215-20. PubMed ID: 1439309
    [Abstract] [Full Text] [Related]

  • 16. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P, Colantonio D, Collacciani A, Casale R, Natali G.
    Panminerva Med; 1991 Aug 15; 33(2):93-110. PubMed ID: 1923560
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.
    Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I.
    Haematologica; 2006 Feb 15; 91(2):200-6. PubMed ID: 16461304
    [Abstract] [Full Text] [Related]

  • 18. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
    Spicka I, Cieslar P, Procházka B, Jirsa M, Chrz M, Gregora E, Klener P.
    Cas Lek Cesk; 2000 Apr 12; 139(7):208-12. PubMed ID: 10916207
    [Abstract] [Full Text] [Related]

  • 19. Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma.
    Pérez-Simón JA, Valverde B, Martínez A, Tabernero D, Almeida J, Gutierrez N, San Miguel JF, Orfao A.
    Cytometry; 1999 Feb 15; 38(1):24-9. PubMed ID: 10088973
    [Abstract] [Full Text] [Related]

  • 20. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003 Feb 15; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.